Commodore Capital LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001831942
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 33 positions · Total reported value $1.50B · Top-10 concentration 55.8% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 53.7% · 5 new · 9 cut · 8 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +32.0% · vs SPY +17.2% · Prev Value $1.73B — last quarter positions weighted by this quarter price moves · ranking
In its Q4 2025 13F filing, Commodore Capital LP disclosed 33 equity positions with a combined reported value of $1.50B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.8% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2025 were RLAY ($143.82M), ALKS ($99.33M), TYRA ($88.73M). By sector, the heaviest allocations are Health Care 84.6%, Other 15.4%. Versus the prior quarter, allocation shifted toward Health Care (+22.2pp) and away from Other (-22.2pp).
Versus the prior quarter, Commodore Capital LP opened 5 new positions, trimmed 9 and fully exited 8, a turnover rate of 53.7% of positions. The portfolio's overlap with the prior quarter was 63% of names.
The largest new positions opened in Q4 2025 were ANRO ($32.45M), PALI ($26.90M), REPL ($13.85M).
Of the 8 positions fully exited versus the prior quarter, the largest were MRUS ($331.88M), AGIO ($93.86M), VRDN ($69.06M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- MRUS MERUS N V · prev qtr: $331.88M
- AGIO AGIOS PHARMACEUTICALS INC COMP · prev qtr: $93.86M
- VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $69.06M
- CDTX CIDARA THERAPEUTICS INC · prev qtr: $56.02M
- TNGX TANGO THERAPEUTICS INC · prev qtr: $12.60M · history
- APGE APOGEE THERAPEUTICS INC · prev qtr: $11.52M
- ENTA ENANTA PHARMACEUTICALS INC COM · prev qtr: $9.58M
- PCSC PERCEPTIVE CAP SOLUTIONS COR · prev qtr: $7.92M
Insider Transactions (Form 4)
Latest Commodore Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Commodore Capital LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 33 positions worth $1.68B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-117168 (status: Approved), registered 2019-08-12
- Regulatory AUM (Form ADV): $2.37B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: commodorecapital.com
Portfolio Structure
- 33 positions · $1.68B reported value (Q2 2026)
- Top 10 holdings = 68.2% of reported value
- Largest position: RLAY (RELAY THERAPEUTICS INC COM) at 13.4%
- Average position size: $50.88M
Sector Tilt
- Health Care 94.7%
- Industrials 3.9%
- Financials 0.6%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 5 new, 6 added, 9 reduced, 8 exited
- 13 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
17.00M | $143.82M | 9.57% | Hold | |
| 2 |
|
3.55M | $99.33M | 6.61% | Add | |
| 3 |
|
3.38M | $88.73M | 5.91% | Hold | |
| 4 |
|
1.80M | $80.68M | 5.37% | Reduce | |
| 5 |
|
2.39M | $78.24M | 5.21% | Add | |
| 6 |
|
2.20M | $78.03M | 5.19% | Reduce | |
| 7 |
|
4.69M | $72.27M | 4.81% | Hold | |
| 8 |
|
2.56M | $69.67M | 4.64% | Reduce | |
| 9 |
|
5.65M | $68.25M | 4.54% | Add | |
| 10 |
|
1.48M | $59.59M | 3.97% | Reduce | |
| 11 |
|
750.00K | $58.36M | 3.88% | Hold | |
| 12 |
|
1.20M | $55.56M | 3.70% | Reduce | |
| 13 |
|
550.00K | $55.32M | 3.68% | Reduce | |
| 14 |
|
1.75M | $53.14M | 3.54% | Hold | |
| 15 |
|
1.89M | $52.43M | 3.49% | Reduce | |
| 16 |
|
2.27M | $43.16M | 2.87% | Reduce | |
| 17 |
|
450.00K | $39.30M | 2.62% | Reduce | |
| 18 |
|
1.00M | $34.01M | 2.26% | Hold | |
| 19 |
|
1.50M | $33.39M | 2.22% | Hold | |
| 20 |
|
7.69M | $32.77M | 2.18% | Hold | |
| 21 |
|
1.82M | $32.45M | 2.16% | New | |
| 22 |
|
11.45M | $26.90M | 1.79% | New | |
| 23 |
|
2.00M | $26.78M | 1.78% | Reduce | |
| 24 |
|
1.00M | $25.01M | 1.67% | Reduce | |
| 25 |
|
3.40M | $22.13M | 1.47% | Add | |
| 26 |
|
4.40M | $16.46M | 1.10% | Hold | |
| 27 |
|
1.43M | $13.85M | 0.92% | New | |
| 28 |
|
5.40M | $11.06M | 0.74% | Hold | |
| 29 |
|
816.33K | $9.33M | 0.62% | New | |
| 30 |
|
483.00K | $8.77M | 0.58% | Hold | |
| 31 |
|
250.00K | $8.47M | 0.56% | New | |
| 32 |
|
464.40K | $3.52M | 0.23% | New | |
| 33 |
|
18.85K | $1.47M | 0.10% | Reduce | |
FAQ
What did Commodore Capital LP buy in 2025-Q4?
In its 2025-Q4 13F filing, Commodore Capital LP reported 33 equity positions worth $1.50B in aggregate; its largest disclosed positions were RLAY ($143.82M), ALKS ($99.33M), TYRA ($88.73M).
How large is Commodore Capital LP's portfolio?
Commodore Capital LP reported $1.50B of long equity holdings across 33 positions as of 2025-Q4. Top-10 holdings account for 55.8% of reported value.
What is Commodore Capital LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.